Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Market price (% of par)
-
86.4%
-
Total 13F principal
-
$257,683,037
-
Principal change
-
+$4,792,295
-
Total reported market value
-
$224,077,029
-
Number of holders
-
25
-
Value change
-
+$11,646,891
-
Number of buys
-
12
-
Number of sells
-
11
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q3 2024
As of 30 Sep 2024,
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by
25 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$257,683,037
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., OAKTREE CAPITAL MANAGEMENT LP, Linden Advisors LP, Graham Capital Management, L.P., SILVERBACK ASSET MANAGEMENT LLC, CAPSTONE INVESTMENT ADVISORS, LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, AQR Arbitrage LLC, and Point72 Asset Management, L.P..
This page lists
25
institutional bondholders reporting positions
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.